Citadel Advisors’s Aegerion Pharmaceuticals AEGR Stock Holding History

Citadel Advisors’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-10,900	Closed	-$16K	–	8177
2016 Q2	$16K	Sell	10,900 -3,300	-23%	-$7.55K	﹤0.01%	6683
2016 Q1	$53K	Sell	14,200 -10,500	-43%	-$65K	﹤0.01%	6237
2015 Q4	$249K	Buy	24,700 +3,800	+18%	+$45.7K	﹤0.01%	5504
2015 Q3	$284K	Sell	20,900 -10,100	-33%	-$180K	﹤0.01%	5653
2015 Q2	$588K	Buy	31,000 +4,400	+17%	+$95.2K	﹤0.01%	4714
2015 Q1	$696K	Sell	26,600 -18,100	-40%	-$461K	﹤0.01%	4435
2014 Q4	$936K	Sell	44,700 -42,800	-49%	-$1.08M	﹤0.01%	3848
2014 Q3	$2.92M	Buy	87,500 +40,500	+86%	+$1.26M	﹤0.01%	2479
2014 Q2	$1.51M	Sell	47,000 -10,700	-19%	-$398K	﹤0.01%	3018
2014 Q1	$2.66M	Buy	57,700 +20,300	+54%	+$1.19M	﹤0.01%	2352
2013 Q4	$2.65M	Buy	37,400 +6,000	+19%	+$459K	﹤0.01%	2253
2013 Q3	$2.69M	Sell	31,400 -7,700	-20%	-$653K	﹤0.01%	2126
2013 Q2	$2.48M	Buy	+39,100	New	+$2.08M	﹤0.01%	2284

Citadel Advisors's AEGR Position: Q4 2016 in Review

Citadel Advisors sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 21,603 shares — an estimated $64K sold.

Citadel Advisors first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $3.27M in Q2 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Citadel Advisors reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Citadel Advisors sold 21,603 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $64K.
Citadel Advisors first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Citadel Advisors's Aegerion Pharmaceuticals position peaked at $3.27M in Q2 2014.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.